Livingstone E, Zimmer L, Hassel JC, Fluck M, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet 2022 Sep 9. pii: S0140-6736(22)01654.
PMID: 36099927